REGENXBIO Inc. - Common Stock, par value $0.0001 per share (RGNX)

Historical Holders from Q3 2015 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
RGNX on Nasdaq
Shares outstanding
51,136,131
Price per share
$14.40
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
41,385,428
Total reported value
$399,433,802
% of total 13F portfolios
0%
Share change
-652,997
Value change
-$3,670,471
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
166
Price from insider filings
$14.40
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of REGENXBIO Inc. - Common Stock, par value $0.0001 per share (RGNX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Redmile Group, LLC 9.9% $43,942,300 5,062,477 Redmile Group, LLC 30 Jun 2025
JPMORGAN CHASE & CO 7.4% $34,806,291 3,698,862 JPMORGAN CHASE & CO. 31 Dec 2024
BlackRock, Inc. 7.3% -34% $34,616,925 -$16,819,095 3,678,738 -33% BlackRock, Inc. 31 Mar 2025
BlackRock Portfolio Management LLC 6.2% $25,726,922 3,133,608 BlackRock Portfolio Management LLC 30 Jun 2025
VANGUARD GROUP INC 6% $28,097,808 2,985,952 The Vanguard Group 31 Dec 2024
STATE STREET CORP 4.4% $20,568,858 2,185,851 STATE STREET CORPORATION 31 Dec 2024
As of 30 Sep 2025, REGENXBIO Inc. - Common Stock, par value $0.0001 per share (RGNX) has 166 institutional shareholders filing 13F forms. They hold 41,385,428 shares. of 51,136,131 outstanding shares (81%) .

Top 25 institutional shareholders own 68% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BlackRock, Inc. 12% 6,370,893 -5.7% 0% $61,479,117
Redmile Group, LLC 9.2% 4,693,389 -1.7% 4.4% $45,291,204
JPMORGAN CHASE & CO 7.9% 4,037,248 +4.8% 0% $38,959,444
VANGUARD GROUP INC 6.5% 3,338,098 -2.4% 0% $32,212,645
STATE STREET CORP 3.9% 1,984,878 +7.7% 0% $19,154,073
GOLDMAN SACHS GROUP INC 3.6% 1,852,214 +3.8% 0% $17,873,866
MORGAN STANLEY 3.3% 1,704,268 +71% 0% $16,446,190
AQR CAPITAL MANAGEMENT LLC 2.5% 1,289,655 +39% 0.01% $12,445,170
GEODE CAPITAL MANAGEMENT, LLC 2.2% 1,125,548 -0.26% 0% $10,863,725
DIMENSIONAL FUND ADVISORS LP 2.2% 1,105,027 -1.6% 0% $10,664,120
Integral Health Asset Management, LLC 2.2% 1,100,000 +57% 0.77% $10,615,000
22NW, LP 1.8% 923,679 0% 4.6% $8,913,502
Assenagon Asset Management S.A. 1.4% 705,403 +23% 0.01% $6,807,139
Nuveen, LLC 1.1% 552,147 +31% 0% $5,328,219
Voss Capital, LP 0.98% 500,000 -13% 0.28% $4,825,000
Invenomic Capital Management LP 0.83% 426,904 0.22% $4,119,624
BANK OF AMERICA CORP /DE/ 0.81% 415,306 -27% 0% $4,007,704
NORTHERN TRUST CORP 0.78% 401,010 +0.23% 0% $3,869,746
ACADIAN ASSET MANAGEMENT LLC 0.78% 399,132 +66% 0.01% $3,849,000
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.77% 391,988 +1.2% 0% $3,782,684
STIFEL FINANCIAL CORP 0.63% 320,410 +3% 0% $3,092,001
RENAISSANCE TECHNOLOGIES LLC 0.61% 309,486 -58% 0% $2,986,540
JANE STREET GROUP, LLC 0.57% 291,162 +20% 0% $2,809,714
Qube Research & Technologies Ltd 0.56% 284,831 -38% 0% $2,748,619
Trexquant Investment LP 0.53% 271,539 -52% 0.03% $2,620,351

Institutional Holders of REGENXBIO Inc. - Common Stock, par value $0.0001 per share (RGNX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 1,263,139 $18,179,781 +$6,866,731 1,440% 7
2025 Q3 41,385,428 $399,433,802 -$3,670,471 965% 166
2025 Q2 42,035,725 $345,140,942 +$5,513,913 821% 159
2025 Q1 41,667,225 $297,962,085 -$1,501,158 715% 163
2024 Q4 42,074,510 $325,173,475 -$15,537,348 773% 175
2024 Q3 43,665,569 $458,056,433 -$8,522,130 1,049% 184
2024 Q2 43,782,930 $512,285,979 +$5,420,902 1,170% 180
2024 Q1 42,534,646 $895,831,731 +$95,824,018 2,107% 185
2023 Q4 38,123,027 $684,323,807 +$18,843,309 1,795% 167
2023 Q3 37,072,487 $610,280,035 -$2,249,035 1,646% 157
2023 Q2 37,122,782 $742,048,193 +$3,963,188 1,999% 165
2023 Q1 37,009,156 $699,776,275 +$18,824,498 1,891% 170
2022 Q4 35,702,552 $809,736,875 +$5,376,487 2,268% 180
2022 Q3 35,093,974 $927,284,018 -$30,479,732 2,643% 173
2022 Q2 36,159,183 $893,093,296 +$28,890,952 2,470% 157
2022 Q1 34,902,249 $1,157,712,999 -$21,017,474 3,318.97% 181
2021 Q4 35,507,306 $1,160,896,124 +$58,351,051 3,269.95% 168
2021 Q3 33,398,271 $1,400,353,918 -$3,046,167 4,192% 177
2021 Q2 33,460,640 $1,299,751,931 +$26,836,789 3,884.97% 168
2021 Q1 32,853,108 $1,120,584,466 +$187,839,315 3,410.99% 178
2020 Q4 27,329,284 $1,239,697,831 -$41,654,835 4,536% 182
2020 Q3 28,512,126 $785,403,793 -$29,743,448 2,752% 162
2020 Q2 29,376,827 $1,082,072,585 +$20,048,711 3,682.98% 174
2020 Q1 28,922,545 $936,893,202 -$29,109,226 3,238% 160
2019 Q4 29,584,479 $1,212,076,877 -$13,179,927 4,097% 178
2019 Q3 29,248,667 $1,041,238,768 -$21,895,746 3,560% 165
2019 Q2 29,447,574 $1,510,592,208 -$22,838,253 5,136.98% 184
2019 Q1 30,143,203 $1,727,382,727 +$15,646,108 5,731% 206
2018 Q4 29,941,433 $1,255,681,603 +$31,694,613 4,194.93% 178
2018 Q3 28,543,303 $2,154,975,590 +$194,166,110 7,550.02% 198
2018 Q2 26,028,733 $1,867,750,691 +$332,228,528 7,175% 174
2018 Q1 22,371,972 $667,791,727 +$29,287,426 2,984.99% 118
2017 Q4 21,584,761 $717,686,392 +$5,112,723 3,324.99% 106
2017 Q3 21,399,716 $704,035,906 -$14,361,368 3,295% 87
2017 Q2 22,655,785 $447,763,347 +$37,345,656 1,975% 86
2017 Q1 20,796,965 $401,380,019 +$94,928,884 1,930% 86
2016 Q4 18,300,126 $339,456,250 +$28,424,124 1,855.01% 77
2016 Q3 16,939,017 $237,123,842 +$3,104,010 1,401% 71
2016 Q2 17,911,156 $143,725,600 +$9,894,905 800% 67
2016 Q1 16,627,713 $179,564,518 +$4,021,922 1,080% 62
2015 Q4 15,040,714 $247,165,923 -$9,897,144 1,659.99% 65
2015 Q3 14,305,786 $310,215,000 +$310,214,985 2,203% 47